LUNGevity and Hamoui Foundations Issue RFA for Research Into RET-positive Lung Cancer
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.
- WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.
- The Hamoui Foundation/LUNGevity RET-positive Award aims to address this gap by funding research to improve outcomes for patients with RET-positive lung cancer.
- "In 2021, when we announced our first partnership with Hamoui Foundation, it was clear that without philanthropic funding in this area, the research would not happen," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research.
- "We awarded $1 million in research grants to gain insights into understanding non-genomic mechanisms of drug resistance in RET-positive lung cancer, leveraging existing FDA-approved drugs to treat RET-positive lung cancer, and studying the structural changes to altered RET proteins.